Semaglutide is FDA-approved for use only in adults who are obese or overweight with comorbidities
Research suggests that after stopping GLP-1 medications, A1C, fasting blood glucose, body weight, waist circumference and systolic blood pressure can increase, so your provider may want to repeat labs, adjust other medications or monitor your blood sugar more closely
Great price
adults who are overweight and have a weight-related medical problem (e.g., blood pressure, type 2 diabetes, or high cholesterol) To reduce the risk of major adverse CV events in: adults with established cardiovascular disease who have obesity or are overweight
But semaglutide can cause insomnia and tirzepatide insomnia is also reported
W Elliott for help with the immunohistochemistry